Alpharma (ALO) NDA For EMBEDA Accepted By FDA for Priority Review
More News related to ALO
- Unusual 11 Mid-Day Movers 11/14: FUQI, LVS, ALO, SUTR Higher; MDTH, CY, OEH, SLH Lower
- Notable Analyst Rating Changes 11/14: CLX, LDK, ALO, URBN Upgraded; GSK, EMR, LHO, UDR Downgraded
- Cowen & Co Upgrades Alpharma (ALO) to Outperform
- Alpharma (ALO) Tops Q3 EPS by 3c; Guides
- DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective
More News related to FDA
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Alpharma Inc. (NYSE: ALO) announced that the FDA has advised the Company that its New Drug Application for EMBEDA Capsules has been accepted and designated for priority review. The priority review status provides for a review period of six months from the date of submission. The EMBEDA Capsule NDA was submitted on June 30, 2008.
Related Categories
FDAStocks Mentioned
-0.69Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
